α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial

α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial

<p>Abstract</p> <p>Background</p> <p>High-grade gliomas including glioblastoma multiforme (GBM) are among the most malignant and aggressive of tumors, and have a very poor prognosis despite a temozolomide-based intensive treatment. Therefore, a novel therapeutic approac...

Full description

Bibliographic Details
Main Authors: Akiyama Yasuto, Oshita Chie, Kume Akiko, Iizuka Akira, Miyata Haruo, Komiyama Masaru, Ashizawa Tadashi, Yagoto Mika, Abe Yoshiaki, Mitsuya Koichi, Watanabe Reiko, Sugino Takashi, Yamaguchi Ken, Nakasu Yoko
Format: Article
Language:English
Published: BMC 2012-12-01
Series:BMC Cancer
Subjects:
Dendritic cell
Immunotherapy
High-grade glioma
HLA-A24
Phase I trial
Online Access:http://www.biomedcentral.com/1471-2407/12/623

Internet

http://www.biomedcentral.com/1471-2407/12/623

Similar Items